{"id":56014,"date":"2023-04-19T18:06:15","date_gmt":"2023-04-19T16:06:15","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cala-introduces-next-generation-system-and-accelerates-leadership-in-bioelectronic-medicine\/"},"modified":"2023-04-19T18:06:15","modified_gmt":"2023-04-19T16:06:15","slug":"cala-introduces-next-generation-system-and-accelerates-leadership-in-bioelectronic-medicine","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cala-introduces-next-generation-system-and-accelerates-leadership-in-bioelectronic-medicine\/","title":{"rendered":"Cala Introduces Next Generation System and Accelerates Leadership in Bioelectronic Medicine"},"content":{"rendered":"
\n

\nThe company will present new clinical and economic evidence at the upcoming 2023 American Academy of Neurology Annual Meeting<\/p>\n

SAN MATEO, Calif.–(BUSINESS WIRE)–Cala<\/a>, the bioelectronic medicine leader setting a new standard of patient care for chronic disease, will preview the next generation of its wearable neuromodulation system and the results of two studies at the 2023 American Academy of Neurology (AAN) Annual Meeting, held from April 22-27, 2023, in Boston, MA.<\/p>\n

<\/a><\/p>\n

\nCala will debut the next generation Transcutaneous Afferent Patterned Stimulation (TAPS) system for essential tremor and now action hand tremors associated with Parkinson\u2019s disease. TAPS therapy gives patients back the control to do what matters in their daily lives without the side effects of traditional medications. The new product will be commercially available in the second half of 2023.<\/p>\n

\n\u201cWe\u2019re excited to share a preview of our next generation device. Cala continues our mission to transform the standard of care through innovative neuroscience and data-driven therapies,\u201d said Renee Ryan, CEO of Cala. \u201cWe are committed to empowering people to get back to their lives with confidence and ease.\u201d<\/p>\n

\nVisit Cala at booth #961 to experience the new product with the patient portal, where patients can see their therapy results and share it with providers.<\/p>\n

\nKate Rosenbluth, Ph.D, Founder and Chief Scientific Officer at Cala, will be presenting at the Emerging Neurologic Care Presentation Stage on Sunday, April 23, from 12:30 \u2013 12:50 p.m. ET. In the session titled \u201cElectricity as Medicine \u2013 Cala TAPS is the First & Only FDA Cleared Non-invasive Therapy for Hand Tremor,\u201d Rosenbluth will provide an overview of the science and clinical evidence for Cala TAPS therapy.<\/p>\n

\nNew data on the burden of essential tremor and new features of the latest TAPS system will be presented at AAN in the \u201cMovement Disorders: Essential Tremor and Other Tremor Disorders\u201d poster session on Tuesday, April 25, from 8:00 \u2013 9:00 a.m. ET:<\/p>\n